Skip to main content
Log in

Antiproliferative role of vitamin D and its analogs – a brief overview

  • Published:
Molecular and Cellular Biochemistry Aims and scope Submit manuscript

Abstract

The active metabolite of vitamin D, 1α, 25-dihydroxyvitamin D3 [1,25(OH)2D3] – a seco-steroid hormone is a pivotal regulator of cellular proliferation and differentiation those are independent of its classical function of calcium homeostasis and bone mineralization. The existence of the nuclear vitamin D receptor (VDR) has been found in numerous tissues in different organs, which are the so-called 'non-classical' targets of this seco-steroid hormone. Vitamin D has been documented as a potent antiproliferative agent in different tissues and cells. Epidemiological studies reveal a negative correlation between physiological level of vitamin and cancer risk. Studies using animal models clearly demonstrate protective role of vitamin D in different cancer types by the reduction in tumor progression and by monitoring biochemical parameters. Experiments with cultured human and animal cancer cell lines show similar antiproliferative role of vitamin D manifested by up or down regulations of crucial genes leading to inhibition of cellular growth. Hypercalcemia hinders broad-spectrum therapeutic uses of vitamin D in cancer chemotherapy. Application of vitamin D analogs having similar chemical structures or other compounds having vitamin D like actions but lacking calcemic adverse effects are getting significant attention towards rational therapeutics to treat cancer. The current review focuses on the application of vitamin D and its analogs in different forms of cancer and on the molecular mechanism involved in vitamin D mediated inhibition in cellular proliferation, cell cycle, induction of apoptosis and tumor suppression, which may eventually evolve as a meaningful cancer therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Reichel H, Koeffler HP, Norman AW: The role of the vitamin D endocrine system in health and disease. N Engl J Med 320: 980-991, 1989

    Google Scholar 

  2. Bouillon R, Okamura WH, Norman AW: Structure-function relationships in the vitamin D endocrine system. Endocr Rev 16: 200-257, 1995

    Google Scholar 

  3. Christakos S, Raval-Pandya M, Wernyj RP, Yang W: Genomic mechanisms involved in the pleiotropic actions of 1,25-dihydroxyvitamin D3. Biochem J 316: 361-371, 1996

    Google Scholar 

  4. Cippitelli M, Fionda C, Di Bona D, Di Rosa R, Lupo A, Mario Piccoli M et al.: Negative regulation of CD95 ligand gene expression by vitamin D3 in T lymphocytes. J Immunol 168: 1154-1166, 2002

    Google Scholar 

  5. Lemire JM: Immunomodulatory actions of 1,25-dihydroxyvitamin D3. J Steroid Biochem Mol Biol 53: 599-602, 1995

    Google Scholar 

  6. Rigby WF: The immunobiology of vitamin D. Immunol Today 9: 54-58, 1988

    Google Scholar 

  7. Piemonti L, Monti P, Sironi M, Fraticelli P, Leone BE, Dal Cin E et al: Vitamin D3 affects differentiation, maturation, and function of human monocyte-derived dendritic cells. J Immunol 164: 4443-4451, 2000

    Google Scholar 

  8. Penna G, Adorini L: 1α,25-Dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 164: 2405-2411, 2000

    Google Scholar 

  9. Provvedini DM, Tsoukas DC, Deftos LJ, Manolagas SC: 1,25-dihydroxyvitamin D3 receptors in human leukocytes. Science 221: 1181-1183, 1983

    Google Scholar 

  10. Mangelsdorf DJ, Koeffler HP, Donaldson CA, Pike JW, Haussler MR: 1,25-Dihydroxyvitamin D3-induced differentiation in a human promyelocytic leukemia cell line (HL-60): Receptor-mediated maturation to macrophage-like cells. J Cell Biol 76: 1-6, 1985

    Google Scholar 

  11. Minghetti PP, Norman AW: 1,25 (OH)2-vitamin D3 receptors: Gene regulation and genetic circuitry. FASEB J 2: 3043-3053, 1988

    Google Scholar 

  12. Niles RM: Use of vitamins A and D in chemoprevention and therapy of cancer: Control of nuclear receptor expression and function. Vitamins, cancer and receptors. Adv Exp Med Biol 375: 1-15, 1995

    Google Scholar 

  13. Norman AW: Vitamin D. In: R. Dulbecco (ed). Encyclopedia of Human Biology. Academic Press, Orlando, FL, 1997, pp 749-762

    Google Scholar 

  14. DeLuca HF, Zierold C: Mechanisms and functions of vitamin D. Nutr Rev 56: S4-S10, 1998

    Google Scholar 

  15. Carlberg C: Critical analysis of 1α,25-dihydroxyvitamin D3 response elements. In: A.W. Norman, R. Bouillon, M. Thomasset (eds). Vitamin D: Chemistry, Biology and Clinical Applications of the Steroid Hormone. University of California, Riverside, 1997, pp 268-275

    Google Scholar 

  16. Weitberg AB, Weizman SA, Clark FP, Stossel TP: Effects of anti-oxidants on oxidant-induced sister chromatid exchange. J Clin Invest 75: 1835-1841, 1985

    Google Scholar 

  17. Gerner JM, Domenech M: 25-Hydroxyvitamin D levels in patients treated with high-dosage ergo-and cholecalciferol. Clin Pathol 30: 144-150, 1977

    Google Scholar 

  18. Mawer EB, Hann JT, Beny JL, Davies M: Vitamin D metabolism in patients intoxicated with ergocalciferol. Clin Sci 68: 135-141, 1985

    Google Scholar 

  19. Rizzoli R, Storemann C, Ammann P, Banjour JP: Hypercalcemia and hyperosteolysis in vitamin D intoxication: Effects of clodronde therapy. Bone 15: 193-198, 1994

    Google Scholar 

  20. Finlay IG, Stewart GJ, Ahkter J, Morris DL: A phase one study of the hepatic arterial administration of 1,25-dihydroxyvitamin D3 for liver cancers. J Gastroenterol Hepatol 16: 333-337, 2001

    Google Scholar 

  21. Garland FC, Garland CF, Young JF: Geographic variation in breast cancer mortality in the United States: A hypothesis involving exposure to solar radiation. Prev Med 19: 614-622, 1990

    Google Scholar 

  22. Garland CF, Comstock GW, Garland FC, Helsing KJ, Shaw EK, Gorham ED: Serum 25-hydroxyvitamin D and colon cancer: Eight-year prospective study. Lancet 2: 1176-1178, 1989

    Google Scholar 

  23. Schwartz GG, Hulka BS: Is Vitamin D deficiency a risk factor for possible for prostate cancer (hypothesis)? Anticancer Res. 0: 1307-1312, 1990

    Google Scholar 

  24. Holt PR, Arber N, Halmos B, Forde K, Kissileff H, McGlynn KA et al.: Colonic epithelial cell proliferation decreases with increasing levels of serum 25-hydroxy vitamin D. Cancer Epidemiol Biomarkers Prev 11: 113-119, 2002

    Google Scholar 

  25. Habuchi T, Suzuki T, Sasaki R, Wang L, Sato K, Satoh S et al.: Association of vitamin D receptor gene polymorphism with prostate cancer and benign prostatic hyperplasia in Japanese population. Cancer Res 60: 305-308, 2000

    Google Scholar 

  26. Hutchinson PE, Osborne JE, Lear JT, Smith AG, Bowers PW, Morris PN et al.: Vitamin D receptor polymorphisms are associated with altered prognosis in patients with malignant melanoma. Clin Cancer Res 6: 498-504, 2000

    Google Scholar 

  27. Platz AE, Hankinson SE, Hollis BW, Colditz GA, Hunter DJ, Speizer FE et al.: Plasma 1,25-dihydroxy-and 5-hydroxyvitamin D and Adenomatous polyps of the distal colorectum. Cancer Epidemiol Biomarkers Prev 9: 1059-1065, 2000

    Google Scholar 

  28. Sardar S, Chatterjee M, Ghosh S, Roy K: Role of vitamin D3 on the activity patterns of hepatic drug metabolizing enzymes in transplantable murine lymphoma. Cancer Invest 14: 328-334, 1996

    Google Scholar 

  29. Makishima M, Lu TT, Xie W, Whitfield GK, Domoto H, Evans RM et al.: Vitamin D receptor as an intestinal bile acid sensor. Science 296: 1313-1316, 2002

    Google Scholar 

  30. Tsoukas CD, Provedini DM, Manolagas SC: 1,25-Dihydroxyvitamin D3 a novel immunoregulatory hormone. Science 224: 1438-1448, 1984

    Google Scholar 

  31. Shabahang M, Buras RR, Davoodi F, Schumaker LM, Nauta RJ, Uskokovic MR, Brenner RV, Evans SRT: Growth inhibition of HT-29 human colon cancer cells by analogs of 1,25-dihydroxyvitamin D3. Cancer Res 54: 4057-4064, 1994

    Google Scholar 

  32. Lointier P, Wargovich MJ, Saez S, Levin B, Wildrick DM, Boman BM: The role of vitamin D3 in the proliferation of a human colon cancer cell line in vitro. Anticancer Res 7: 817-822, 1987

    Google Scholar 

  33. Thomas MG, Tebbutt S, Williamson RCN: Vitamin D and its metabolites inhibit cell proliferation in human rectal mucosa and a colon cancer cell line. Gut 33: 1660-1663, 1992

    Google Scholar 

  34. Pines J: Cyclins and cyclin-dependent kinases: A biochemical view. Biochem J 308: 697-711, 1995

    Google Scholar 

  35. Jiang H, Lin J, Su ZZ, Collart FR, Huberman E, Fisher PB: Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21WAF1/CIP1, expression in the absence of p53. Oncogene 9: 3397-3406, 1994

    Google Scholar 

  36. Wang QM, Jones JB, Studzinski GP: Cyclin-dependent kinase inhibitor p27 as a mediator of the G1-S phase block induced by 1,25-dihydroxyvitamin D3 in HL60 cells. Cancer Res 56: 264-267, 1996

    Google Scholar 

  37. Munker R, Kobayashi T, Elstner E, Norman AW, Uskokovic M, Zhang W et al.: A new series of vitamin D analogs is highly active for clonal inhibition, differentiation, and induction of WAF1 in myeloid leukemia. Blood 88: 2201-2209, 1996

    Google Scholar 

  38. Campbell MJ, Elstner E, Holden S, Uskokovic M, Koeffler HP: Inhibition of proliferation of prostate cancer cells by a 19-nor-hexafluoride vitamin D3 analog involves the induction of p21waf1, p27kip1 and Ecadherin. J Mol Endocrinol 19: 15-27, 1997

    Google Scholar 

  39. Hansen CM, Rohde L, Madsen MW, Hansen D, Colston KW, Pirianov G et al.: MCF-7/VDR: A new vitamin D resistant cell line. J Cell Biochem 82: 422-436, 2001

    Google Scholar 

  40. Inoue T, Kamiyama J, Sakai T: Sp1 and NF-Y synergistically mediate the effect of vitamin D3 in the p27kip1 gene promoter that lacks vitamin D response elements. J Biol Chem 274: 32309-32317, 1999

    Google Scholar 

  41. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V et al.: Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269: 682-685, 1995

    Google Scholar 

  42. Liu W, Asa SL, Fantus IG, Walfish PG Ezzat S: Vitamin D arrests thyroid carcinoma cell growth and induces p27 dephosphorylation and accumulation through PTEN/akt-dependent and-independent pathways. Am J Pathol 160: 511-519, 2002

    Google Scholar 

  43. Yamaoka K, Marion SL, Gallegos A, Haussler MR: 1,25-Dihydroxyvitamin D3 enhances the growth of tumors in athymic mice inoculated with receptor rich osteosarcoma cells. Biochim Biophys Res Commun 139: 1292-1298, 1986

    Google Scholar 

  44. Kohl NE, Conner MW, Gibbs JB, Graham SL: Development of inhibitors of protein farnesylation as potential chemotherapeutic agents. J Cell Biochem 22(suppl): 145-150, 1995

    Google Scholar 

  45. Clairmont A, Tessmann D, Stock A, Nicolai S, Stahl W, Sies H: Induction of gap junctional intercellular communication by vitamin D in human skin fibroblasts is dependent on the nuclear vitamin D receptor. Carcinogenesis 17: 1389-1391, 1996

    Google Scholar 

  46. Hotz-Wagenblatt A, Shalloway D: Gap junctional communication and neoplastic transformation. Crit Rev Oncog 4: 541-558, 1993

    Google Scholar 

  47. Yu W, Dahl G, Werner R: The connexin 43 gene is responsive to estrogen. Proc R Soc Land B Biol 255: 125-132, 1994

    Google Scholar 

  48. Wang X, Nicholas MP, Studzinski GP: Long-term exposure of HL60 cells to 1,25-dihydroxyvitamin D3 reduces their tumorigenecity: A model for cancer chemoprevention. Proc Soc Exp Biol Med 215: 399-404, 1997

    Google Scholar 

  49. Brelvi ZS, Studzinski GP: Inhibition of DNA synthesis by an inducer of differentiation of leukemic cells, 1α,25 dihydroxyvitamin D3 precedes down regulation of the c-myc genes. J Cell Physiol 128: 171-179, 1986

    Google Scholar 

  50. Quack M, Clarin A, Binderup E, Bjorkling F, Hansen CM, Carlberg C: Structural variants of the vitamin D analog EB1089 reduce its ligand sensitivity and promoter selectivity. J Cell Biochem 71: 340-350, 1998

    Google Scholar 

  51. Mathiasen IS, Lademann U, Jäättelä M: Apoptosis induced by vitamin D compounds in breast cancer cells is inhibited by Bcl-2 but does not involve known caspases or p53. Cancer Res 59: 4848-4856, 1999

    Google Scholar 

  52. Elstner E, Israeli ML, Umiel T, Le J, Grillier I, Said J et al: Combination of potent 20-epi-vitamin D3 analog (KH 1060) with 9-cis-retinoic acid irreversibility inhibits clonal growth, decreases bcl-2 expression, and induces apoptosis in HL-60 leukemic cells. Cancer Res 56: 3570-3576, 1996

    Google Scholar 

  53. Shkenazi A, Dixit VM: Death receptor: Signalling and modulation. Science 281: 1305-1308, 1998

    Google Scholar 

  54. Saudens DE, Christansen C, Schultz JF, Lawrence WD, Malviya VK, Malone JM et al.: Inhibition of c-myc in breast and ovarian carcinoma cells by 1,25-dihydroxyvitamin D3, retinoic acid and dexamethasone. Anti-Cancer Drugs 4: 201-208, 1993

    Google Scholar 

  55. Koga M, Eisman JA, Sutherland RL: Regulation of epidermal-growth factor receptor levels by 1,25-dihydroxyvitamin D3, in human breast cancer cells. Cancer Res 48: 2734-2739, 1988

    Google Scholar 

  56. Vandewalle B, Hornez Z, Wattez N, Revillion F, Lefebvre T: Vitamin D3 derivatives and breast-tumor cell growth: Effect on intracellular calcium and apoptosis. Int J Cancer 61: 806-811, 1995

    Google Scholar 

  57. Wood AC, Waters CM, Garner A, Hickman JA: Changes in c-myc expression and the kinetics of dexamethane induced programmed cell death (apoptosis) in human lymphoid leukemia cells. Br J Cancer 69: 663-669, 1994

    Google Scholar 

  58. Brady M, Binderum J, Colston KW: EB 1089, a synthetic analog of vitamin D, induces apoptosis in breast cancer cells in vivo and in vitro. Br J Pharmacol 125: 953-962, 1998

    Google Scholar 

  59. Swami S, Krishnan AV, Feldman D: 1α,25-Dihydroxyvitamin D3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells. Clin Cancer Res 6: 3371-3379, 2000

    Google Scholar 

  60. Jensen SS, Madsen MW, Lukas J, Binderup L, Bartek J: Inhibitory effects of 1α,25-dihydroxyvitamin D3 on the G1-S phase-controlling machinery. Mol Endocrinol 15: 1370-1380, 2001

    Google Scholar 

  61. Koli K, Keski-Oja J: 1, 25-dihydroxyvitamin D3 enhances the expression of transforming growth factor β1 and its latent form binding protein in cultured breast carcinoma cells. Cancer Res 55: 1440-1446, 1995

    Google Scholar 

  62. Verlinden L, Verstuyf A, Van Camp M, Marcelis S, Sabbe K, Zhao XY et al.: Two novel 14-Epi-analogs of 1,25-dihydroxyvitamin D3 inhibit the growth of human breast cancer cells in vitro and in vivo. Cancer Res 60: 2673-2679, 2000

    Google Scholar 

  63. Simboli-Campbel M, Narvaez CJ, VanWeelden K, Tenniswood M, Welsch JE: Comparative effects of 1,25(OH)2D3 and EB1089 on cell cycle kinetics and apoptosis in MCF-7 breast cancer cells. Breast Cancer Res Treat 42: 31-41, 1997

    Google Scholar 

  64. Rozen F, Pollak M: Inhibition of insulin-like growth factor I receptor signaling by the vitamin D analog EB1089 in MCF-7 breast cancer cells: A role for insulin-like growth factor binding proteins. Int J Oncol 15: 589-594, 1999

    Google Scholar 

  65. Lazzaro G, Agadir A, Qing W, Poria M, Mehta RR, Moriarty RM et al.: Induction of differentiation by alpha-hydroxyvitamin D5 in T47D human breast cancer cells and its interaction with vitamin D receptors. Eur J Cancer 36: 780-786, 2000

    Google Scholar 

  66. Chen A, Davis BH, Bissonnette M, Scaglione-Sewell B, Brasitus TA: 1,25-Dihydroxyvitamin D3 stimulates activator protein-1-dependent caco-2 cell differentiation. J Biol Chem 274: 35505-35513, 1999

    Google Scholar 

  67. Kane KF, Langman MJS, Williams GR: Antiproliferative responses of two human colon cancer cell lines to vitamin D3 are differentially modified by 9-cis retinoic acid. Cancer Res 56: 623-632, 1996

    Google Scholar 

  68. Caligo MA, Cipollini G, Petrini M, Valentini P, Bevilacqua G: Down regulation of NM23.H1, NM23.H2 and c-myc genes during differentiation induced by 1,25 dihydroxyvitamin D3. Leuk Res 20: 161-167, 1996

    Google Scholar 

  69. Peleg S, Qiu H, Reddy S, Harris D, Van Q, Estey EH et al.: 1,25-Dihydroxy vitamin D3 and its analogs inhibit acute myelogenous leukemia progenitor proliferation by suppressing interleukin-1β production. J Clin Invest 100: 1716-1724, 1997

    Google Scholar 

  70. Kole KL, Gyetko MR, Simpson RU, Sitrin RG: Cacitriol-mediated modulation of urokinase-type plasminogen activator and plasminogen activator inhibitor-2. Biochem Pharmacol 41: 585-591, 1991

    Google Scholar 

  71. Seol JG, Kim ES, Park WH, Jung CW, Kim BK, Lee YY: Telomerase activity in acute myelogenous leukaemia: Clinical and biological implications. Br J Haematol 100: 156-165, 1998

    Google Scholar 

  72. Song LN: Demonstration of vitamin D receptor expression in a human megakaryoblastic leukemia cell line: Regulation of vitamin D receptor mRNA expression and responsiveness by forskolin. J Steroid Biochem Mol Biol 57: 265-274, 1996

    Google Scholar 

  73. Kaneko A, Suzuki S, Hara M, Mori J, Kumagai M, Yajima H et al.: 1,25-Dihydroxyvitamin D3 suppresses the expression of the VCAM-1 receptor, VLA-4 in human leukemic HL-60 cells. Biochem Biophys Res Commun 255: 371-376, 1999

    Google Scholar 

  74. Park WH, Seol JG, Kim ES, Binderup L, Koeffler HP, Kim BK et al.: The induction of apoptosis by a combined 1,25(OH)2D3 analog, EB1089 and TGF-β1 in NCI-H929 multiple myeloma cells. Int J Oncol 20: 533-542, 2002

    Google Scholar 

  75. Muto A, Kizaki M, Yamato K, Kawai Y, Kamata-Matsushita M, Ueno H et al.: 1,25-Dihydroxyvitamin D3 induces differentiation of a retinoic acid-resistant acute promyelocytic leukemia cell line (UF-1) associated with expression of p21WAF1/CIP1 and p27KIP1. Blood 93: 2225-2233, 1999

    Google Scholar 

  76. Wang QM, Luo X, Kheir A, Coffman FD, Studzinski GP: Retinoblastoma protein-overexpressing HL60 cells resistant to 1,25-dihydroxyvitamin D3 display increased CDK2 and CDK6 activity and shortened G1 phase. Oncogene 16: 2729-2737, 1999

    Google Scholar 

  77. Zhao XY, Peehl DM, Navone NM, Feldman D: 1α,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms. Endocrinology 141: 2548-2556, 2000

    Google Scholar 

  78. Rashid SF, Moore JS, Walker E, Driver PM, Engel J, Edwards CE et al.: Synergistic growth inhibition of prostate cancer cells by 1α,25 dihydroxyvitamin D3 and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin A. Oncogene 20: 1860-1872, 2001

    Google Scholar 

  79. Huynh H, Pollak M, Zhang JC: Regulation of insulin-like growth factor (IGF) II and IGF binding protein 3 autocrine loop in human PC-3 prostate cancer cells by vitamin D metabolite 1,25(OH)2D3 and its analog EB1089. Int J Oncol 13: 137-143, 1998

    Google Scholar 

  80. Hedlund TE, Moffatt KA, Miller GJ: Vitamin D receptor expression is required for growth modulation by 1α,25-dihydroxyvitamin D3 in the human prostatic carcinoma cell line ALVA-31. J Steroid Biochem Mol Biol 58: 277-288, 1996

    Google Scholar 

  81. Zhuang SH, Burnstein KL: Antiproliferative effect of 1α,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. Endocrinology 139: 1197-1207, 1998

    Google Scholar 

  82. Saha BK, Bishayee A, Kanjilal NB, Chatterjee M: 1α,25-dihydroxyvitamin D3 inhibits hepatic chromosomal aberrations, DNA strand breaks and specific DNA adducts during rat hepatocarcinogenesis. Cell Mol Life Sci 58: 1141-1149, 2001

    Google Scholar 

  83. Saha BK, Sarkar A, Basak R, Chatterjee M: 1α,25-dihydroxyvitamin D3 suppresses the effect of streptozotocin-induced diabetes during chemical rat liver carcinogenesis. Cell Biol Int 25: 227-237, 2001

    Google Scholar 

  84. Basak R, Bhattacharya R, Chatterjee M: 1α,25-dihydroxyvitamin D3 inhibits rat liver ultrastructural changes in diethylnitrosamine-initiated and phenobarbital promoted rat hepatocarcinogenesis. J Cell Biochem 81: 357-367, 2001

    Google Scholar 

  85. Basak R, Chatterjee M: Combined supplementation of vanadium and 1α,25-dihydroxyvitamin D3 inhibit placental glutathione S-transferase positive foci in rat liver carcinogenesis. Life Sci 68: 217-231, 2000

    Google Scholar 

  86. Basak R, Saha BK, Chatterjee M: Inhibition of diethylnitrosamine-induced rat liver chromosomal aberrations and DNA-strand breaks by synergistic supplementation of vanadium and 1α,25-dihydroxyvitamin D3. Biochim Biophys Acta 1502: 273-282, 2000

    Google Scholar 

  87. Basak R, Basu M, Chatterjee M: Combined supplementation of vanadium and 1α,25-dihydroxyvitamin D3 inhibit diethylnitrosamine-induced rat liver carcinogenesis. Chem Biol Interact 128: 1-18, 2000

    Google Scholar 

  88. Hansen CM, Binderup L, Hamberg KJ, Carlberg C: Vitamin D and cancer: Effects of 1,25(OH)2D3 and its analogs on growth control and tumorigenesis. Front Biosci 6: D820-D848, 2001

    Google Scholar 

  89. Chatterjee M: Vitamin D and genomic stability. Mutat Res 475: 69-87, 2001

    Google Scholar 

  90. van den Bemd GJ, Chang GTG: Vitamin D and vitamin D analogs in cancer treatment. Curr Drug Targets 3: 85-94, 2002

    Google Scholar 

  91. Hisatake J, Kubota T, Hisatake Y, Uskokovic M, Tomoyasu S, Koeffler HP: 5,6-trans-16-ene-vitamin D3: A new class of potent inhibitors of proliferation of prostate, breast, and myeloid leukemic cells. Cancer Res 59: 4023-4029, 1999

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Banerjee, P., Chatterjee, M. Antiproliferative role of vitamin D and its analogs – a brief overview. Mol Cell Biochem 253, 247–254 (2003). https://doi.org/10.1023/A:1026072118217

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1026072118217

Navigation